Literature DB >> 17308208

Medical treatment of benign prostatic hyperplasia.

Stephen S Connolly1, John M Fitzpatrick.   

Abstract

Pharmaceutical preparations are commonly used for benign prostate hyperplasia. This article reviews the current understanding of the natural history of the condition and the literature regarding medical treatment.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17308208      PMCID： PMC2805943          DOI： 10.1136/pgmj.2006.050724

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  106 in total

Review 1.  The placebo effect and randomized trials: analysis of conventional medicine.

Authors:  Mark A Moyad
Journal:  Urol Clin North Am       Date:  2002-02       Impact factor: 2.241

Review 2.  Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction.

Authors:  Anastasios Athanasopoulos; Petros Perimenis
Journal:  Expert Opin Pharmacother       Date:  2005-11       Impact factor: 3.889

3.  Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.

Authors:  S A McNeill; T B Hargreave; Claus G Roehrborn
Journal:  Urology       Date:  2005-01       Impact factor: 2.649

4.  Management of symptomatic BPH in the US: who is treated and how?

Authors:  R Bruskewitz
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

5.  Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia.

Authors:  Michael C Kearney; Jonathan B Bingham; Ryan Bergland; Patricia Meade-D'Alisera; Peter J Puchner
Journal:  J Urol       Date:  2002-06       Impact factor: 7.450

Review 6.  Pygeum africanum for benign prostatic hyperplasia.

Authors:  T Wilt; A Ishani; R Mac Donald; I Rutks; G Stark
Journal:  Cochrane Database Syst Rev       Date:  2002

7.  The development and validation of a quality-of-life measure to assess partner morbidity in benign prostatic enlargement.

Authors:  H Sells; J Donovan; P Ewings; R P MacDonagh
Journal:  BJU Int       Date:  2000-03       Impact factor: 5.588

8.  Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group.

Authors:  P Abrams; C C Schulman; S Vaage
Journal:  Br J Urol       Date:  1995-09

9.  Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies.

Authors:  G Tian; R A Mook; M L Moss; S V Frye
Journal:  Biochemistry       Date:  1995-10-17       Impact factor: 3.162

10.  Preliminary study of the frequency of benign prostatic hyperplasia and prostatic cancer in China.

Authors:  F L Gu; T L Xia; X T Kong
Journal:  Urology       Date:  1994-11       Impact factor: 2.649
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.